secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001193125-25-194994
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical gets Nasdaq MVLS deficiency notice; stockholders approve reverse stock split
--------------------------------------------------------------------------------

- Received Nasdaq notice on Aug 28, 2025 for non-compliance with $50M MVLS requirement for continued listing on Global Market.
- Company has 180 days until Feb 24, 2026 to regain compliance; may consider transfer to Nasdaq Capital Market.
- At special meeting Aug 29, 2025, stockholders approved reverse stock split in range of 1-for-5 to 1-for-15 to address bid price deficiency.
- Reverse stock split approved with 46.5M for, 2.2M against, 459k abstained out of 49.2M shares present.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000119312525194994/0001193125-25-194994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000119312525194994/clsd-20250828.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-194994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer